Drug news

Valeant Pharmaceuticals and Progenics announce the US launch of Relistor (methylnaltrexone bromide) Tablets to treat opioid-induced constipation in adults with chronic non-cancer pain .

Read time: 1 mins

Last updated:7th Sep 2016

Published:7th Sep 2016

Source: Pharmawand

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc.announced the U.S. commercial launch of Relistor (methylnaltrexone bromide) Tablets, which is now available for prescribing. Relistor Tablets (450 mg once daily) were approved by the FDA for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approval for Kalydeco to treat infants with cystic fibrosis ages 1 month and older.- Vertex.

Vertex Pharmaceuticals announced that the European Commission has granted approval for the label expansion of Kayydeco (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

1 mins

Drug news

Novavax is prepared to deliver protein-based non-mRNA JN.1 COVID-19 vaccine in line with WHO recommendation this fall.

Novavax is Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line with WHO Recommendation this Fall

1 min

Drug news

CHMP positive for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.- Idorsia Ltd.

Idorsia Ltd announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

1 min

See all news